GlassScriptPhysician profile
Edmond G Feuille
NPI 1033166152
$7,407.72
in general payments reported to CMS, 2019-2025
37 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $625 · 2021: $1,088 · 2022: $1,091 · 2023: $1,421 · 2024: $1,000 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,266 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,266.44 |
| Education | $229.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,810.34 | 2019-2024 | |
| Hologic Sales and Service, LLC | $1,026.57 | 2019-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $668.74 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $514.30 | 2021-2025 | |
| Pfizer INC. | $439.19 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $362.42 | 2019-2025 | |
| Intuitive Surgical, INC. | $299.20 | 2019-2025 | |
| Myriad Women'S Health, INC. | $256.07 | 2023 | Myrisk |
| Therapeuticsmd, INC. | $235.31 | 2019-2021 | |
| Myovant Sciences INC. | $197.19 | 2021-2022 | |
| Daiichi Sankyo INC. | $190.75 | 2021-2022 | |
| Medtronic, INC. | $190.57 | 2022-2023 | Truclear |
| Sumitomo Pharma America, INC. | $187.42 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $159.85 | 2025 | Zurzuvae |
| Allergan, INC. | $147.87 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $92.08 | 2019 | |
| Agile Therapeutics, INC. | $90.97 | 2021-2024 | Twirla |
| Conmed Corporation | $62.50 | 2020 | |
| Exeltis, USA INC. | $58.97 | 2021-2024 | Slynd |
| Duchesnay USA Incorporated | $46.19 | 2019 | |
| Evofem Biosciences, INC. | $44.58 | 2021 | |
| Mylan Pharmaceuticals INC. | $42.48 | 2021 | |
| Ascend Therapeutics US, LLC | $35.10 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $22.22 | 2024 | Myrisk |
| Northgate Technologies, INC. | $21.49 | 2024 | Stimsite |
| Merck Sharp & Dohme LLC | $20.39 | 2024 | Gardasil 9, Gardasil |
| Shield Therapeutics INC | $20.26 | 2025 | |
| Smith+Nephew, INC. | $19.77 | 2020 | |
| Coopersurgical, INC. | $18.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.11 | 2022 | |
| Heron Therapeutics, INC. | $18.01 | 2022 | |
| Scynexis, INC. | $16.37 | 2022 | |
| Gynesonics, INC. | $15.95 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exact Sciences Corporation | $15.63 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $14.38 | 2019 | |
| Convatec INC. | $14.27 | 2024 | |
| Hologic INC | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmond Feuille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.